

BioTime Inc. (BTIM.OB) - The inclusion of BioTime in our Stem Cell Sector is a bit of a stretch at this point. We do so because BioTime's CEO, Dr. Michael West, founded Geron Corporation and was also with Advanced Cell Technology, two of our Stem Cell Sector firms. Additionally, Biotime seems to be placing an emphasis in Stem Cell technology as indicated by its recent letter of intent signed with International Stem Cell to jointly produce and distribute research products from human embryonic stem cell technology.

BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (*low temperature*) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications.

BioTime's lead product, Hextend, is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary **Embryome Sciences, Inc.**, through which it plans to develop new medical and research products using embryonic stem cell technology.